Treatment with 300 mg IV eptinezumab in adults with chronic migraine resulted in rapid and sustained reduction in the number of headache days that was largely sustained up to 84 weeks, according to a ...

The combination of a β-adrenergic receptors (AR) blocker and a carbonic anhydrase (CA, EC 4.2.1.1) inhibitor in eye drops formulations is one of the most clinically used treatment for glaucoma. A ...

Migraines are a common ailment worldwide, affecting nearly 15% of the global population. At times, they can be debilitating enough to interfere with daily activities. Despite a multitude of treatment ...

Patients with migraine discontinued treatment less often with atogepant and experienced a greater reduction in mean monthly ...

Atogepant 60 mg once daily leads to meaningful weight loss in patients with overweight or obesity receiving preventive ...

A GLP-1 drug led to fewer days with headaches, a small pilot study of migraine sufferers shows. It may work by lowering pressure inside the head.